Free Trial

Azitra Q2 2023 Earnings Report

Azitra logo
$0.30 -0.02 (-6.73%)
As of 03/28/2025 04:10 PM Eastern

Azitra EPS Results

Actual EPS
-$70.80
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Azitra Revenue Results

Actual Revenue
$0.17 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Azitra Announcement Details

Quarter
Q2 2023
Time
N/A

Conference Call Resources

Remove Ads

Azitra Earnings Headlines

Now I look stupid. Real stupid...
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Maxim Group Reaffirms Their Buy Rating on Azitra Inc (AZTR)
See More Azitra Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Azitra? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Azitra and other key companies, straight to your email.

About Azitra

Azitra (NYSEAMERICAN:AZTR), an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. It has a collaboration with Bayer. The company was incorporated in 2014 and is based in Branford, Connecticut.

View Azitra Profile

More Earnings Resources from MarketBeat